Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG)
Abstract
Publication Date:
2010
Abstract:
Background: The prognosis of patients (pts) with recurrent HGG is poor with a median survival of 3 to 6 months. To date, no second line of treatment is recognized as standard.
Enhanced angiogenesis has been recognized as a marker of HGG. Antiangiogenetic agents combined to irinotecan (I) have shown major antitumor activity in recurrent HGG. Sunitinib
(S) is a selective inhibitor of multiple tyrosine kinases including VEGFR and PDGFR that crosses the blood-brain barrier. We investigated the safety and activity of the combination ..
Enhanced angiogenesis has been recognized as a marker of HGG. Antiangiogenetic agents combined to irinotecan (I) have shown major antitumor activity in recurrent HGG. Sunitinib
(S) is a selective inhibitor of multiple tyrosine kinases including VEGFR and PDGFR that crosses the blood-brain barrier. We investigated the safety and activity of the combination ..
CRIS type:
4.2 Abstract in Atti di convegno
List of contributors:
Grisanti, Salvatore; R., Pedersini; Vd, Ferrari; R., Liserre; F., Consoli; Poliani, Pietro Luigi; BUGLIONE DI MONALE E BASTIA, Michela; G., Rangoni; E., Montini; E., Simoncini
Book title:
ASCO Meeting Abstracts
Published in: